Summary
43.98 -0.25(-0.57%)09/27/2024
Harrow Health Inc (HROW)
Harrow Health Inc (HROW)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.58 | -2.38 | 1.29 | 109.43 | 246.57 | 206.05 | 671.58 | -63.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 43.98 | |
| Open | 44.48 | |
| High | 44.93 | |
| Low | 43.39 | |
| Volume | 147,499 | |
| Change | -0.26 | |
| Change % | -0.58 | |
| Avg Volume (20 Days) | 267,171 | |
| Volume/Avg Volume (20 Days) Ratio | 0.55 | |
| 52 Week Range | 7.60 - 47.49 | |
| Price vs 52 Week High | -7.39% | |
| Price vs 52 Week Low | 478.68% | |
| Range | -1.12 | |
| Gap Up/Down | -1.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,569 | |
| EBIDTA | 7,935,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 16.13 | |
| Book Value | 0.6170 | |
| Earnings Per Share | -0.3840 | |
| EPS Estimate Current Quarter | -0.0200 | |
| EPS Estimate Next Quarter | 0.0400 | |
| EPS Estimate Current Year | -0.4400 | |
| EPS Estimate Next Year | 0.3500 | |
| Diluted EPS (TTM) | -0.3840 | |
| Revenues | ||
| Profit Marging | -0.1411 | |
| Operating Marging (TTM) | 0.0896 | |
| Return on asset (TTM) | 0.0462 | |
| Return on equity (TTM) | -0.4591 | |
| Revenue TTM | 66,883,000 | |
| Revenue per share TTM | 2.5280 | |
| Quarterly Revenue Growth (YOY) | 0.2990 | |
| Quarterly Earnings Growth (YOY) | -0.6400 | |
| Gross Profit (TTM) | 34,408,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 14.8063 | |
| Revenue Enterprise Value | 3.8046 | |
| EBITDA Enterprise Value | 29.9263 | |
| Shares | ||
| Shares Outstanding | 26,902,800 | |
| Shares Float | 20,931,426 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.45 | |
| Institutions (%) | 55.16 | |
09/25 12:02 EST - businesswire.com
Harrow Announces Nashville Expansion
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville. Harrow was originally founded in 2012 in San Diego, California. In 2019, Harrow relocated its corporate headquarters to Nashville, Tennessee. Since 2019, Harrow has continued to invest in Nashvill.
Harrow Announces Nashville Expansion
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville. Harrow was originally founded in 2012 in San Diego, California. In 2019, Harrow relocated its corporate headquarters to Nashville, Tennessee. Since 2019, Harrow has continued to invest in Nashvill.
09/03 07:00 EST - businesswire.com
Harrow to Present at Three Investor Conferences in September in New York
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York: H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel) September 9-11, 2024 Company will present at 8:00 a.m. ET on September 10, 2024 Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club) September 12, 2024 1x1.
Harrow to Present at Three Investor Conferences in September in New York
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York: H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel) September 9-11, 2024 Company will present at 8:00 a.m. ET on September 10, 2024 Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club) September 12, 2024 1x1.
08/17 00:14 EST - seekingalpha.com
Are AI Stocks A Better Investment Then Value Stocks?
One can find stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares investing in the Magnificent Seven Stocks to high total return dividend value stocks. The best-balanced stocks provide potential returns three times that of the Magnificent Seven.
Are AI Stocks A Better Investment Then Value Stocks?
One can find stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares investing in the Magnificent Seven Stocks to high total return dividend value stocks. The best-balanced stocks provide potential returns three times that of the Magnificent Seven.
08/16 15:42 EST - seekingalpha.com
Harrow: Bulls On Parade
Harrow stock is reaching new highs with significant short interest, but operational strength is driving a covering rally. Harrow is an eye care pharmaceutical company targeting the North American market with a comprehensive portfolio of products. Q2 growth for Harrow was impressive, with strong performance across all operating segments and a positive outlook for future revenue expansion.
Harrow: Bulls On Parade
Harrow stock is reaching new highs with significant short interest, but operational strength is driving a covering rally. Harrow is an eye care pharmaceutical company targeting the North American market with a comprehensive portfolio of products. Q2 growth for Harrow was impressive, with strong performance across all operating segments and a positive outlook for future revenue expansion.
08/07 18:35 EST - zacks.com
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
08/01 03:29 EST - seekingalpha.com
Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks
I have a diversified portfolio of stocks, funds, and bonds. My stocks are primarily dividend paying value stocks. One can find dividend stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares the earnings growth, dividend yield, current valuation, and estimated future return of 53 stocks.
Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks
I have a diversified portfolio of stocks, funds, and bonds. My stocks are primarily dividend paying value stocks. One can find dividend stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares the earnings growth, dividend yield, current valuation, and estimated future return of 53 stocks.
07/30 09:50 EST - zacks.com
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
07/03 09:41 EST - benzinga.com
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
06/24 11:42 EST - seekingalpha.com
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in $1.50 of incremental FCF/share in 2025, and then up from there, so that Triesence may by itself be worth more than the current share price. There are huge synergies with Iheezo, as the same buyers can be targeted for both drugs.
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in $1.50 of incremental FCF/share in 2025, and then up from there, so that Triesence may by itself be worth more than the current share price. There are huge synergies with Iheezo, as the same buyers can be targeted for both drugs.
06/21 03:46 EST - zacks.com
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
06/20 07:00 EST - businesswire.com
Harrow Provides TRIESENCE® Relaunch Update
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unrespon.
Harrow Provides TRIESENCE® Relaunch Update
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unrespon.
06/07 06:30 EST - investorplace.com
The Top 7 Growth Stocks to Buy and Hold Until 2030
If you're looking for the best growth stocks to buy and hold through 2030, you should look into the many solid businesses other than the top tech mega-caps. I believe expanding your core growth holdings into some of these quality businesses is a good idea, as they have sticky revenues and solid growth over the coming years.
The Top 7 Growth Stocks to Buy and Hold Until 2030
If you're looking for the best growth stocks to buy and hold through 2030, you should look into the many solid businesses other than the top tech mega-caps. I believe expanding your core growth holdings into some of these quality businesses is a good idea, as they have sticky revenues and solid growth over the coming years.
06/06 08:00 EST - businesswire.com
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.'s proprietary fast‑dissolving.
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.'s proprietary fast‑dissolving.
06/05 07:00 EST - businesswire.com
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study,.
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study,.
05/15 07:00 EST - businesswire.com
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA) Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024 Craig-Hallum 21st Annual Institutional In.
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA) Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024 Craig-Hallum 21st Annual Institutional In.
05/14 10:48 EST - seekingalpha.com
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Chase Knickerbocker - Craig-Hallum Brooks O'Neil - Lake Street Capital Operator Good day, everyone, and welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call.
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Chase Knickerbocker - Craig-Hallum Brooks O'Neil - Lake Street Capital Operator Good day, everyone, and welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call.
05/13 16:01 EST - businesswire.com
Harrow Announces First Quarter 2024 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations f.
Harrow Announces First Quarter 2024 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations f.
05/13 07:00 EST - businesswire.com
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saha.
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saha.
05/02 12:20 EST - seekingalpha.com
Harrow: Merits A Buy On Sales Potential
Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Vevye, a dry eye therapy, also has a significant total addressable market and has shown promising early returns since its launch.
Harrow: Merits A Buy On Sales Potential
Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Vevye, a dry eye therapy, also has a significant total addressable market and has shown promising early returns since its launch.
05/02 04:42 EST - seekingalpha.com
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headaches for healthcare providers. Harrow will definitely miss Q1 2024 earnings estimates as a result. Although the cyberattack is widely known, sell side estimates have not been updated to reflect the impact.
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headaches for healthcare providers. Harrow will definitely miss Q1 2024 earnings estimates as a result. Although the cyberattack is widely known, sell side estimates have not been updated to reflect the impact.